This month Erik Haeffler, Vice President of Manufacturing Services at Recipharm took to the Medicine Maker alongside other serialisation experts to discuss whether the industry is ready for the upcoming regulatory deadlines and to dispel the misconception that serialisation is simply ‘adding a label to the box.’

If companies can seize the opportunities that serialisation offers, then there is undoubtedly value beyond compliance

Compliance with the European Falsified Medicines Directive (FMD) goes beyond adding a unique code to each drug product. It is a complex process that involves IT system creation, regulatory data uploading, new packaging requirements, supply chain adaptation and far more.

In the article, Erik discusses how attitudes to serialisation have changed, the lessons learned so far and the challenges faced by companies throughout the supply chain. He describes the shift to serialisation as a positive step in the supply chain that has been needed for some time. During the roundtable the experts also deliberate over who is responsible for ensuring products are serialised and some of the short and long-term effects and benefits of serialisation on the industry.

Read the full discussion and Erik’s comments from a CDMO perspective here.